MIAMI - Tennsun -- First Choice Neurology is proud to announce a groundbreaking partnership with NeuroDiscovery AI (NDAI), a national leader in artificial intelligence, data analytics, and clinical dashboarding for neurology. This strategic collaboration brings cutting-edge AI capabilities to our practice and connects us with a nationwide prestigious network of leading outpatient neurology groups. Together, we are working to transform the future of neurology by advancing research, optimizing patient outcomes, and elevating standards of care.

Through this collaboration, First Choice Neurology joins a national alliance of leading neurology practices committed to driving innovation in patient care with the world's most extensive longitudinal dataset in neurology. Together, we will utilize AI-powered insights to:

• Revolutionize patient care through AI and extensive medical data
• Monitor treatment outcomes in real-time
• Accelerate research and clinical trials
• Discover new biomarkers & novel targets
• Improve care coordination and efficiency

Today, we stand at the forefront of neurological research, armed with:

• The world's most extensive longitudinal dataset in neurology
• Partnerships with over 470 leading neurology providers across the US
• A comprehensive database consists of multimodal data extracted from 5 M+ patients
• Cutting-edge AI technology to derive meaningful insights from complex data

Advancing Care in Key Neurological Areas
Our partnership with NeuroDiscovery AI allows us to focus on several high-impact areas of neurological research and care:

Multiple Sclerosis (MS) - A chronic autoimmune disorder affecting the central nervous system. With the help of NeuroDiscovery AI, our MS specialists can track disease progression, evaluate treatment efficacy, and explore new therapeutic options more effectively than ever before.

More on tennsun.com

• Heritage at South Brunswick Grand Opening Success!
• $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
• LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
• Marc Soucy's Newest Music Series Approaches Its One Year Mark
• Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities

"The quality and volume of information that NDAI can garner from our records is outstanding. This collaboration provides us with powerful tools to better understand disease patterns and personalize MS treatment strategies. Levels of magnitude are greater than I thought possible. It's a major leap forward in how we care for our MS patients."
— Dr. Bernard Gran, Neurologist, First Choice Neurology

Parkinson's Disease (PD) - A progressive neurodegenerative disorder that affects movement, cognition, and quality of life. Through data-driven research, we're identifying new biomarkers and refining care models that improve long-term outcomes for Parkinson's patients.

Alzheimer's Disease (AD) - One of the leading outpatient neurology groups treating Alzheimer's and other forms of dementia, First Choice Neurology is at the forefront of clinical care and research. NeuroDiscovery AI will allow us to analyze large-scale data sets, assess the real-world effectiveness of new medications, and contribute to developing novel therapies.

NeuroDiscovery AI offers clinicians and researchers millions of data points to investigate new treatments for neurological disorders. "Let's say you want to evaluate and identify a group of 100 women, between the ages of 50-65, with a maternal history of dementia, and track their development of cognitive decline. NDAI can generate that data in a minute as opposed to weeks or months. Do you wish to assess associated genetic markers? That would take another minute. And to correlate common MRI patterns would take just another minute." Dr. Jeff Gelblum believes that "this new computer technology will revolutionize clinical research and treatment protocols."

More on tennsun.com

• Award-winning NJ Author Celebrates New Release and Multi-Author Collaboration
• Therapy 911 Launches Mental Health Social Network to Celebrate Mental Health Awareness Month
• Bosco's Beach Launches Vacation Rentals in Panama City Beach, Florida
• $7.8M Financing Boosts NRx's Expansion with Kadima Institute Acquisition for PTSD and Depression Care: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
• One Park Financial Once Again Honored with Sun Sentinel's Top Workplaces Award for the 8th Time — Achieves Best Ranking Yet in 2025

— Dr. Jeff Gelblum, Neurologist and national authority on the treatment of Alzheimer's, First Choice Neurology

Frontotemporal Dementia (FTD) - A lesser-known but equally devastating condition that affects personality, behavior, and language. Through our partnership, we aim to accelerate research into early detection and management, contributing to broader efforts in combating all forms of dementia.

Migraine and Headache Disorders - One of the most common neurological disorders, often misunderstood and underdiagnosed. Our migraine specialists are now equipped with enhanced tools to track patient responses to medications and identify patterns that may lead to more effective, personalized treatments.

Autism and Developmental Disorders - Neurodevelopmental conditions like autism require a highly individualized and evidence-based approach. With this partnership, our child neurologists and neuropsychologists will be able to integrate behavioral data and clinical metrics to improve diagnosis and track developmental progress over time.

Looking Ahead
We believe that the future of neurology lies at the intersection of clinical expertise, innovative technology, and collaborative research. Our partnership with NeuroDiscovery AI marks an exciting step forward in our journey to lead that transformation. We look forward to working with them and changing the world, together.

To learn more about First Choice Neurology, visit https://www.fcneurology.net/

To learn more about NeuroDiscovery AI, visit https://neurodiscovery.ai/